
Unlocking The Digital Ecosystem Of Healthcare

Roche Diagnostics Investor Day

Tim M. Jaeger MD PhD MBA

20 November 2018



Introduction – Patients Need Certainty

For patients, each diagnosis is an emotional struggle




**Yearly 14M new
cancer cases**

**Survival doubled
since 1970¹**

¹ <https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/incidence>


Introduction – Growing Medical Knowledge

Increasingly difficult for professionals to keep up



Introduction – Layers Of Complexity In Medicine

Layers of interdependent data add complexity at various levels



Introduction – Changes In Healthcare Environment

Healthcare undergoing rapid and fundamental change



Increased understanding
of disease biology



More educated and
empowered patients



Novel technologies and data
sources entering research as
well as clinic



Regulatory environment
evolving for digital
and improved data privacy




Partnerships forming between
non-traditional players



Global demand
for outcome-driven, value-
based healthcare

Roche Group – What Makes Us Different

Unique combination of assets in ONE Roche




Roche uniquely positioned:

- Pharma & Diagnostics under one roof
- Excellence in medicine and biology
- Leading portfolio of therapies
- Reputation as a trusted pioneer
- Global scale and reach
- Strong partnerships



Roche Group – Personalised Healthcare Opportunity

Leverage data to shift focus towards truly individualised patient care



PAST

Blockbuster drugs

One medication for broad categories of patients with a disease



PRESENT

Companion Diagnostics

Advanced diagnostics & targeted medicines for specific groups of people



FUTURE


Personalized healthcare

Individualized treatment & disease management targeted to specific patient



Roche Diagnostics – Clinical Decision Support Opportunity

Clinical Decision Support at the center of care continuum



Diagnostics Information Solutions (DIS) – Strategy Overview

Focus on clinical decision support

Our Vision

Become **leading provider** of data-driven and value-based **clinical decision support solutions** for healthcare **providers** and **patients**

Our Objectives

Improve patient outcomes

Empower our customers

Establish CDS business



Oncology


&



Infectious Disease

What We Do

Clinical Decision Support



Better Patient Care



How We Win

NAVIFY
portfolio

Customer
success


Ecosystem &
partnerships

Data & analytics
capabilities

Culture, Purpose, Impact

DIS Strategy – Clinical Decision Support Framework

Enabled by R&D and supporting value-based care models



DIS Strategy – Clinical Decision Support Elements

Enabled by activities in translational science, data and with payors

Rapid translation
of new
discoveries &
capability
development




**Clinical
Decision
Support**

Aggregated,
longitudinal data
drives high-quality,
differentiated CDS




Incentivizing
provider adoption
of CDS through
payor influence &
provider efficiency



NAVIFY Ecosystem – Decision Support Portfolio Overview

Platform with workflow products, apps and value-added services



¹ NAVIFY Platform, A scalable, secure, and flexible platform enabling DIA teams to collaborate and deliver innovative and compliant cloud-based decision support products

² Workflow Products, e.g. Tumor Board, Oncojourney, Mutation Profiler, Translational Research

³ Decision Support Apps, e.g. Literature Search, Clinical Trial Matching, Guidelines, Immunoprofiling, IRIS Algorithms etc

⁴ Customer valued, data-enabled analytics services. Strong feedback loop to data aggregation and Decision Support Apps.


⁵ Ecosystem of 3rd party CDS App providers and Service providers forming around NAVIFY Platform and Workflows

NAVIFY Ecosystem – NAVIFY® Tumor Board Introduction

First commercially available product, launched in 7 markets (EU/US)

Supporting oncology care teams to review, collaborate, and align on treatment decisions for patients.

A **comprehensive dashboard for cancer care teams** - integrates all the disparate pieces of clinical data from multiple specialists into one useful dashboard built for collaboration.



Now available in select markets



NAVIFY.com/tumorboard

© 2017 Roche Molecular Systems, Inc.

All trademarks recited herein are Roche trademarks

NAVIFY Ecosystem – NAVIFY Tumor Board Workflow Study

Workflow benefits for oncology care teams



¹ <http://www.jpathinformatics.org/article.asp?issn=2153-3539;year=2018;volume=9;issue=1;page=26;epage=26;aulast=krupinski>
 Workflow image source: NAVIFY Tumor Board White Papers on <https://www.navify.com/tumorboard/>





Kren, Jane

Female, 44

MRN 849506933

SUBMIT TO TUMOR BOARD

CANCER INFO

Right breast
Invasive Ductal Carcinoma NOS

c

T2

N1

M0

Stage IIB

p

T2

N1a

M0

Stage IIB

PATIENT HISTORY

APPS



Clinical Trial
Match



Publication
Search

PATIENT HISTORY

EDIT

HISTORY OF PRESENT ILLNESS ⓘ

44-year-old post-menopausal woman who initially presented to her family physician in Nov 2018 with a right breast lump. Mammogram (4th Dec 2018) showed an irregular speculated 2.5mm density in the right upper outer quadrant. Core Needle Biopsy (10th Dec 2018) revealed a poorly differentiated (grade 3) invasive ductal carcinoma. Biomarkers show HER2 negative; ER negative; PgR negative; CK 5/6 negative.

PAST MEDICAL HISTORY ⓘ

Smoking status

10 cigarettes per day (started in 2010)

Alcohol Consumption

20 units per week

Panic Attacks

Attended ED twice for panic attacks (2011, 2013)

Ovarian Cancer

Left ovary low-grade serous carcinoma (2010). Treatment was THS/BSO (09 Sep 2010). No recurrence

Ankle fracture

ORIF for weber B left ankle fracture (2007)

PHYSICAL EXAMINATION ⓘ

Blood Pressure	07 Dec 2018 ⓘ	114/76 mmHg
Heart Rate	07 Dec 2018 ⓘ	73 bpm
Respiratory Rate	07 Dec 2018 ⓘ	14 per/min
Temperature	07 Dec 2018 ⓘ	36.8 Celsius
Height	07 Dec 2018 ⓘ	167 cm
Weight	07 Dec 2018 ⓘ	75 kg
BMI	07 Dec 2018 ⓘ	26.9 kg per sq m
General Observations	07 Dec 2018 ⓘ	Fit & healthy; Anxious
Breast Examination	07 Dec 2018 ⓘ	Lump in right breast upper outer quadrant (mobile, no tenderness); No overlying skin changes; No LN in Axilla
Respiratory Examination	07 Dec 2018 ⓘ	Normal - Good air entry bilateral
Cardiovascular Examination	07 Dec 2018 ⓘ	Normal - HS I+II with no added sounds
Abdominal Examination	07 Dec 2018 ⓘ	Soft & non-tender with normal bowel sounds

SOCIAL HISTORY ⓘ

DATE OF BIRTH

17 Mar 1974

MARITAL STATUS

Married

CHILDREN

1

CONTACT

Mary Johnson
Mother
+1 832 748832

MEDICATIONS ⓘ

Citalopram (10mg; OM; PO)
Paracetamol (1g; QDS; PO)
Multi-vitamin tablet (1 per day; OM; PO)

ALLERGIES

Penicillin, Peanuts

CARE TEAM

Dr. Ana Smith, Dr. Luisa Chen

TIMELINE

CREATE NEW

All events


Multidisciplinary
29 May 2019

Past events



Molecular Profile report

01 Apr 2019





Radiation therapy


05 Mar 2019

Radiation to the chest wall and right axilla



Ultrasound

29 Dec 2018




2018



Mammogram

29 Dec 2018





Surgery


29 Dec 2018

MRI Guided, Wire Localization, Right Lumpectomy with Right Axillary Sentinel Lymph Node





Breast tumor board
21 Dec 2018

PDF





NAVIFY Ecosystem – Portfolio Evolution

Continuously adding functionalities to expand value



Commercial – Market Opportunity

Worldwide market opportunity for CDS growing rapidly



Total Health IT market ~\$26B

Source: Adapted from DeciBio CDSS Market Landscape Mar 2017

Total CDS Market \$1.6B (2018) growing to \$2.9B (2023)

Commercial – Competitive Landscape

Traditional and non-traditional vendors leveraging respective capabilities

Health IT

Market incumbents with large install-base. Incremental improvements in CDS. Partner or acquire for more complex functionality

MedTech

Tangential players with large install-base of hospital instruments. Upsell existing customers with integrated value-added solutions

Technology

New entrants leveraging deep capabilities in technology, AI, hardware, and user experience.

Startups

Small startups & specialty providers offering data, niche solutions, or broad menu of apps. Innovative, agile, but lack scale

Clinical Decision Support (CDS) Market

Opportunities


- Comprehensive, integrated portfolio backed by industry expertise
- Non-competitive & R&D collabos
- Equity investments (e.g. Flatiron)
- Ecosystem partnering

“Roche, GE to Develop Integrated Digital Diagnostics for Oncology, Critical Care Treatment”



Commercial – SaaS Business Model

Speed and scale: create sockets first, revenue follows




To get to high customer lifetime value and recurring revenue streams

- R&D and M&D investment
- Landgrab
- Farming


Collaboration – GE Healthcare Strategic Partnership

Co-develop and co-market integrated digital diagnostic software products



Collaboration – Accenture Integration Partnership

Connecting disparate clinical information to improve decision making



Closing – Unlocking The Digital Healthcare System

Committed to driving clinical decision support towards an ecosystem

Roche uniquely positioned to help navigate increasing complexity in healthcare and deliver on promise of **personalised healthcare**.

Delivering **clinical decision support solutions** informed by science and driven by data with the **NAVIFY Decision Support Portfolio**.

Entering new market to **improve clinical workflow efficiency & eventually quality** through **strong partnerships** that help build a **digital ecosystem**.



Doing now what patients need next